Germany · Delayed Price · Currency is EUR Armata Pharmaceuticals Statistics
Total Valuation
FRA:TG1N has a market cap or net worth of EUR 211.57 million. The enterprise value is 351.72 million.
| Market Cap | 211.57M |
| Enterprise Value | 351.72M |
Important Dates
The next estimated earnings date is Monday, March 16, 2026.
| Earnings Date | Mar 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 36.33M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 2.09% |
| Float | 10.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 49.12 |
| PB Ratio | -2.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.80 |
| EV / Sales | 80.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -15.04 |
Financial Position
The company has a current ratio of 0.12
| Current Ratio | 0.12 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -6.48 |
| Interest Coverage | -2.22 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -22.20% |
| Return on Invested Capital (ROIC) | -24.32% |
| Return on Capital Employed (ROCE) | 66.13% |
| Revenue Per Employee | 71,792 |
| Profits Per Employee | -666,229 |
| Employee Count | 60 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +187.38% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +187.38% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 66.01 |
| Average Volume (20 Days) | 75 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.58 |
Income Statement
In the last 12 months, FRA:TG1N had revenue of EUR 4.31 million and -39.97 million in losses. Loss per share was -1.89.
| Revenue | 4.31M |
| Gross Profit | -17.94M |
| Operating Income | -28.42M |
| Pretax Income | -39.97M |
| Net Income | -39.97M |
| EBITDA | -27.15M |
| EBIT | -28.42M |
| Loss Per Share | -1.89 |
Balance Sheet
The company has 12.58 million in cash and 151.44 million in debt, giving a net cash position of -138.86 million.
| Cash & Cash Equivalents | 12.58M |
| Total Debt | 151.44M |
| Net Cash | -138.86M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -81.47M |
| Book Value Per Share | -2.25 |
| Working Capital | -104.85M |
Cash Flow
In the last 12 months, operating cash flow was -23.03 million and capital expenditures -352,000, giving a free cash flow of -23.38 million.
| Operating Cash Flow | -23.03M |
| Capital Expenditures | -352,000 |
| Free Cash Flow | -23.38M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -659.87% |
| Pretax Margin | -928.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:TG1N does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.16% |
| Shareholder Yield | -0.16% |
| Earnings Yield | -18.89% |
| FCF Yield | -11.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.0714285714.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.0714285714 |
Scores
FRA:TG1N has an Altman Z-Score of -8.47 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.47 |
| Piotroski F-Score | 3 |